NEW YORK ─ Rapid test developer Abingdon Health on Friday announced it has inked an exclusive manufacturing agreement with BioSure UK.
Under the terms of the agreement, York, UK-based Abingdon will manufacture BioSure’s COVID-19 lateral flow tests at Abingdon’s UK-based York and Doncaster sites.
Financial and other terms of the agreement were not disclosed.
Abingdon CEO Chris Yates said in a statement that the deal builds on its long-term collaboration with Essex, UK-based BioSure.
In March, the firms announced that they had inked a nonexclusive sales and distribution agreement for Abingdon's rapid SARS-CoV-2 neutralizing antibody test, AbC-19.